GOP Senators Criticize FDA Pace on Mifepristone Safety Review, Threaten Legislative Action

2026-02-12

The BareStory

Republican senators expressed frustration on Tuesday following a closed-door briefing with FDA Commissioner Marty Makary regarding a safety review of the abortion drug mifepristone. Senators Josh Hawley and Bill Cassidy criticized the agency for what they described as a lack of progress on a promised study of the medication, which is used in a majority of abortions in the United States.

Following the meeting, Senator Hawley stated that Commissioner Makary provided no timeline for the review or confirmation of its current status. Hawley said he has "no confidence" the agency is acting with urgency and announced plans to involve Congress. He indicated he may seek to place restrictions on the drug through government funding legislation or a standalone bill in the coming weeks. Senator Cassidy, who arranged the briefing, echoed these sentiments, calling the lack of progress disappointing.

In response to the criticism, a Department of Health and Human Services spokesperson referred to a previous statement noting that the FDA is conducting the study properly. The statement explained that such reviews often take a year or more to complete to ensure scientific standards are met.

To support his call for stricter oversight, Hawley cited a study by the Ethics and Public Policy Center which alleged that nearly 11% of women who used the drug experienced serious adverse events within 45 days. The senator argued for the reinstatement of safeguards removed by the Biden administration, including requirements for in-person doctor visits to obtain prescriptions and follow-up care.

The dispute occurs as the Trump administration faces pressure to restrict access to abortion pills via mail and telemedicine. While the administration reportedly asked judges in ongoing lawsuits to delay rulings until the FDA’s study is finished, conservative lawmakers are pushing for immediate action to limit the drug's availability.

Left Perspective

Shielding Scientific Integrity
Defending Reproductive Autonomy
Resisting Legislative Coercion

Right Perspective

Enforcing Public Safety Standards
Restoring Congressional Oversight
Reinstating Institutional Continuity

Left Perspective

• Shielding Scientific Integrity Valuing the separation of politics and medicine, this camp views the HHS statement regarding the year-long timeline not as delay, but as necessary rigor to ensure "scientific standards are met." The logic holds that expediting a safety review due to pressure from Senators Hawley and Cassidy risks compromising data quality for political expediency. A deliberate process shields the FDA’s findings from becoming a weaponized tool of partisan ideology.

• Defending Reproductive Autonomy Framing the removal of barriers as a victory for civil liberties, this perspective interprets Hawley’s push for "in-person doctor visits" as a tactical regression designed to curb access rather than improve safety. The insistence on reinstating safeguards removed by the Biden administration is viewed as an attempt to utilize bureaucratic hurdles to dismantle the availability of medication used in a majority of U.S. abortions. The priority is preventing the state from effectively banning a procedure through onerous logistical requirements.

• Resisting Legislative Coercion Prioritizing the autonomy of regulatory bodies, this camp views the threat to restrict the drug through "government funding legislation" as a dangerous overstep of legislative power into technocratic territory. The "no confidence" declaration by Hawley is seen as a pretext to bypass the administrative state’s expertise. By threatening the agency's funding, lawmakers are accused of substituting expert consensus with majoritarian political muscle.

Right Perspective

• Enforcing Public Safety Standards Prioritizing the protective role of the state, this camp argues that the EPPC study citing "serious adverse events" in nearly 11% of users necessitates immediate government intervention. The logic dictates that when credible data suggests harm, the "lack of progress" on a safety review is not bureaucratic caution but negligence. The demand to reinstate safeguards is viewed as a moral obligation to restore the standard of care and protect citizens from potential medical complications.

• Restoring Congressional Oversight Valuing the supremacy of elected representatives over unelected officials, this perspective sees Commissioner Makary’s failure to provide a "timeline" or confirmation of status as a breach of accountability. The threat to utilize "standalone bills" or funding legislation is interpreted as a valid exercise of checks and balances against an unresponsive administrative state. If the agency refuses to act with urgency, the legislature is duty-bound to impose order and responsiveness.

• Reinstating Institutional Continuity Focusing on established medical norms, this camp views the previous administration's removal of requirements like "follow-up care" as a reckless deregulation that disrupted the traditional doctor-patient relationship. The push to return to in-person visitation is reasoned not as a restriction, but as a return to prudent medical practice. This side seeks to stabilize the healthcare system by reverting to long-standing protocols that prioritize physical examination over tele-health conveniences.

How it may affect me

As a U.S. reader:

Patients seeking medication abortions via telemedicine could face new barriers if proposed legislative actions successfully mandate in-person doctor visits and follow-up care.

Americans awaiting legal certainty on the availability of abortion pills by mail may see court rulings delayed for a year or more while the FDA completes its safety review.

The federal funding process could become complicated in the coming weeks if lawmakers follow through on threats to attach drug restrictions to government spending legislation.

Those using the drug may eventually be subject to reinstated safety protocols, such as mandatory physical examinations, if arguments regarding adverse event rates drive policy changes.

GOP Senators Criticize FDA Pace on Mifepristone Safety Review, Threaten Legislative Action

The BareStory

Left Perspective

Right Perspective

How it may affect me

Read the story at